Published in Blood Weekly, February 17th, 2000
The study will investigate the use of the RenalTech BetaSorb device as an accessory to hemodialysis in patients with chronic kidney failure. RenalTech has selected San Bortolo Hospital in Vicenza, Italy, as the study site. San Bortolo is one of Europe's premiere dialysis research facilities, and has been instrumental in the testing of new devices to improve the therapy of chronic renal failure patients.
"Our technology addresses a looming health...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.